MRD testing is crucial for high-risk MM patients, aiding in early detection and treatment decisions, despite logistical and insurance barriers. Physicians primarily use MRD to monitor remission, ...

MRD refers to cancer cells remaining post-treatment, undetectable by standard imaging, indicating potential recurrence risk. MRD testing methods include flow cytometry and genetic tests, offering ...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that the National Comprehensive Cancer Network® (NCCN®) has updated its Clinical Practice ...

Molecular residual disease, or MRD, testing is emerging as a powerful tool in breast cancer, offering new visibility into what traditional imaging cannot detect. 1 MRD tests, like the Oncodetect® test ...

April's vote of the FDA Oncology Drug Advisory Committee to support use of MRD-negative CR as an end point for accelerated approval represents a triumph of science, persistence, and collaboration, ...

Clinicians have long relied on clinical risk factors, imaging, and pathology to guide cancer surveillance and adjuvant treatment. However, even after curative-intent surgery and definitive therapy, ...

For patients with early-stage triple-negative breast cancer (TNBC), finishing chemotherapy and surgery should feel like the end of the hardest chapter. But for many, it marks the beginning of a ...

The clearance gives New York clinicians access to the Haystack MRD assay, which detects residual or recurring solid tumour ...

Quest Diagnostics® (NYSE: DGX), a leading provider of diagnostic information services, today announced that the New York State Department of Health's (NYSDOH) Clinical Laboratory Evaluation Program ...

Add Yahoo as a preferred source to see more of our stories on Google. Haystack Oncology focuses on advancing liquid biopsy technologies. Credit: Gorodenkoff ...